Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207058417> ?p ?o ?g. }
- W4207058417 endingPage "3221" @default.
- W4207058417 startingPage "3211" @default.
- W4207058417 abstract "Filgotinib is a potent, oral, JAK1-preferential inhibitor for the treatment of rheumatoid arthritis (RA). This report describes exposure-response (ER) analyses of filgotinib for dose confirmation based on three phase 3 and two phase 2 studies in moderate to severe RA patients.The pharmacokinetic exposures used in ER analyses were derived from population pharmacokinetic analysis. The exposure-efficacy relationships were assessed for efficacy endpoints (ACR20/50/70 and DAS28) over effective area under curve (AUCeff ), the combined exposures of filgotinib and GS-829845 (major, active metabolite), with nonlinear logistic regression models developed. Also, a t-test was performed to compare the exposure between subjects who achieved response and those who did not. For the ER analyses of safety, exposures were examined between subjects who experienced and who did not experience the evaluated safety events, which was conducted separately for filgotinib and GS-829845.The nonlinear logistic regression showed increasing response with increasing exposure, with exposures at 200 mg dose primarily residing on the curve plateau. Also, AUCeff was significantly higher in the subjects who achieved responses compared to those who did not (10 900 vs 9900 h*ng/mL for ACR20, P value < .0001). For exposure-safety analyses, filgotinib and GS-829845 exposures were similar irrespective of the presence/absence of the evaluated safety endpoints, indicating no exposure-safety relationship for common treatment-emergent adverse events (TEAEs)/laboratory abnormalities and serious TEAEs/infections.ER analyses confirmed that filgotinib produced more robust therapeutic effects across the exposure range observed at 200 mg once daily compared to lower doses, and collectively with the lack of exposure-safety relationship, the 200 mg once daily dose was supported for commercialization." @default.
- W4207058417 created "2022-01-26" @default.
- W4207058417 creator A5001083964 @default.
- W4207058417 creator A5004508109 @default.
- W4207058417 creator A5013479458 @default.
- W4207058417 creator A5027087975 @default.
- W4207058417 creator A5041344161 @default.
- W4207058417 creator A5052133090 @default.
- W4207058417 creator A5059158287 @default.
- W4207058417 creator A5068470814 @default.
- W4207058417 creator A5076963248 @default.
- W4207058417 creator A5077361663 @default.
- W4207058417 creator A5088051469 @default.
- W4207058417 date "2022-02-14" @default.
- W4207058417 modified "2023-09-26" @default.
- W4207058417 title "Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies" @default.
- W4207058417 cites W2038254125 @default.
- W4207058417 cites W2051008941 @default.
- W4207058417 cites W2072026013 @default.
- W4207058417 cites W2126087693 @default.
- W4207058417 cites W2561041192 @default.
- W4207058417 cites W2562753811 @default.
- W4207058417 cites W2566103724 @default.
- W4207058417 cites W2592397452 @default.
- W4207058417 cites W2625769798 @default.
- W4207058417 cites W2803973097 @default.
- W4207058417 cites W2887596795 @default.
- W4207058417 cites W2912849003 @default.
- W4207058417 cites W2936120062 @default.
- W4207058417 cites W2962938985 @default.
- W4207058417 cites W2972941060 @default.
- W4207058417 cites W2987819628 @default.
- W4207058417 cites W3124339251 @default.
- W4207058417 cites W3135306353 @default.
- W4207058417 cites W3136549884 @default.
- W4207058417 cites W3136857317 @default.
- W4207058417 cites W4207058417 @default.
- W4207058417 cites W4211144854 @default.
- W4207058417 cites W4240756220 @default.
- W4207058417 doi "https://doi.org/10.1111/bcp.15239" @default.
- W4207058417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35072287" @default.
- W4207058417 hasPublicationYear "2022" @default.
- W4207058417 type Work @default.
- W4207058417 citedByCount "4" @default.
- W4207058417 countsByYear W42070584172021 @default.
- W4207058417 countsByYear W42070584172022 @default.
- W4207058417 countsByYear W42070584172023 @default.
- W4207058417 crossrefType "journal-article" @default.
- W4207058417 hasAuthorship W4207058417A5001083964 @default.
- W4207058417 hasAuthorship W4207058417A5004508109 @default.
- W4207058417 hasAuthorship W4207058417A5013479458 @default.
- W4207058417 hasAuthorship W4207058417A5027087975 @default.
- W4207058417 hasAuthorship W4207058417A5041344161 @default.
- W4207058417 hasAuthorship W4207058417A5052133090 @default.
- W4207058417 hasAuthorship W4207058417A5059158287 @default.
- W4207058417 hasAuthorship W4207058417A5068470814 @default.
- W4207058417 hasAuthorship W4207058417A5076963248 @default.
- W4207058417 hasAuthorship W4207058417A5077361663 @default.
- W4207058417 hasAuthorship W4207058417A5088051469 @default.
- W4207058417 hasBestOaLocation W42070584171 @default.
- W4207058417 hasConcept C112705442 @default.
- W4207058417 hasConcept C126322002 @default.
- W4207058417 hasConcept C151956035 @default.
- W4207058417 hasConcept C197934379 @default.
- W4207058417 hasConcept C2777477808 @default.
- W4207058417 hasConcept C2777575956 @default.
- W4207058417 hasConcept C2908647359 @default.
- W4207058417 hasConcept C71924100 @default.
- W4207058417 hasConcept C90924648 @default.
- W4207058417 hasConcept C98274493 @default.
- W4207058417 hasConcept C99454951 @default.
- W4207058417 hasConceptScore W4207058417C112705442 @default.
- W4207058417 hasConceptScore W4207058417C126322002 @default.
- W4207058417 hasConceptScore W4207058417C151956035 @default.
- W4207058417 hasConceptScore W4207058417C197934379 @default.
- W4207058417 hasConceptScore W4207058417C2777477808 @default.
- W4207058417 hasConceptScore W4207058417C2777575956 @default.
- W4207058417 hasConceptScore W4207058417C2908647359 @default.
- W4207058417 hasConceptScore W4207058417C71924100 @default.
- W4207058417 hasConceptScore W4207058417C90924648 @default.
- W4207058417 hasConceptScore W4207058417C98274493 @default.
- W4207058417 hasConceptScore W4207058417C99454951 @default.
- W4207058417 hasFunder F4320308573 @default.
- W4207058417 hasFunder F4320319293 @default.
- W4207058417 hasIssue "7" @default.
- W4207058417 hasLocation W42070584171 @default.
- W4207058417 hasLocation W42070584172 @default.
- W4207058417 hasLocation W42070584173 @default.
- W4207058417 hasLocation W42070584174 @default.
- W4207058417 hasOpenAccess W4207058417 @default.
- W4207058417 hasPrimaryLocation W42070584171 @default.
- W4207058417 hasRelatedWork W1492229869 @default.
- W4207058417 hasRelatedWork W1499958231 @default.
- W4207058417 hasRelatedWork W1964759623 @default.
- W4207058417 hasRelatedWork W1976890451 @default.
- W4207058417 hasRelatedWork W1996694250 @default.
- W4207058417 hasRelatedWork W1998356222 @default.
- W4207058417 hasRelatedWork W2030336508 @default.